drugset

drugset / Trial / NCT05400317

A Study to Evaluate the Efficacy and Safety of AD-218

NCT05400317 ↗

Phase 3 Recruiting 520 enrolled Addpharma Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-218

Timeline

Start: 2022-07-27
Primary completion: 2026-03-31
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AD-218	Unknown	—	Oral
Comparator	AD-218A	Unknown	—	Oral

Indications